Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget - United States
doi 10.18632/oncotarget.9229
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Pcn94 - Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients With Advanced Renal Cell Carcinoma in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore

International Journal of Technology Assessment in Health Care
Health Policy
2019English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?

Clinical Medicine Insights: Oncology
Oncology
2011English

Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pazopanib Has Equivalent Anti-Tumor Effectiveness and Lower Total Costs Than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy